論文・技術情報追加のお知らせ

①Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

BRAFおよびMEK阻害剤併用療法の眼球有害事象リスクについての不均衡分析研究

対象DB：FAERS

②Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.

ビタミンDによるオランザピン投与に伴う脂質異常症の発症抑制についての研究

対象DB：FAERS

③Vaccines and Atrial Fibrillation: A Real-World Pharmacovigilance Study Based on Vaccine Adverse Event Reporting System.

ワクチンと心房細動についてのリアルワールドpv研究

対象DB：VAERS

④Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.

バイオシミラー製品と生物学的製剤の有害事象報告についての比較研究

対象DB：FAERS

⑤Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.

プロテアソーム阻害剤による心臓有害事象の安全性シグナル、併用薬の影響についての研究

対象DB：FAERS

⑥Adverse effects of proton pump inhibitors (PPIs) on Renal system using Data Mining Algorithms (DMAs).

プロトンポンプ阻害薬が腎臓系に及ぼす影響調査研究

対象DB：FAERS

⑦The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase.

抗糖尿病薬による抗うつ作用の調査研究

対象DB：FAERS,VigiBase